Abstracts tagged "autoimmune diseases and big data"

Abstract Number: 2159 • 2018 ACR/ARHP Annual Meeting
Autoimmune Diseases in Catalonia: A Population Based Study Using a Public Big Data Program
Antoni Sisó-Almirall^1,2,3, Belchin Kostov^1,2,3, Elisenda Martínez Carbonell⁴, Soledad Retamozo^5,6,7, Alejandra Flores-Chavez^8,9,10, S. González-Martínez^1,2,3, Pilar Brito-Zerón⁵, Antoni Dedéu Baraldés¹¹, Jaume Benavent Àreu^1,2,3 and Manuel Ramos-Casals^2,12, ¹Consorci d’Atenció Primària de Salut Barcelona Esquerre (CAPSBE), Barcelona, Spain, ²Departament de Medicina, Universitat de Barcelona, Barcelona, Spain, ³Grup de Recerca Transversal en Atenció Primària, IDIBAPS, Barcelona, Barcelona, Spain, ⁴Agency for Health Quality and Assessment of Catalonia (AQuAS). Ministry of Health, Catalonia., Barcelona, Spain, ⁵Department of Autoimmune Diseases, ICMiD, Hospital Clínic Barcelona, Barcelona, Spain, ⁶Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Córdoba, Consejo Nacional de Investigaciones Científicas y Técnicas (INICSA-UNC-CONICET), Cordoba, Argentina, ⁷Rheumatology Unit, Hospital Privado Universitario de Córdoba, Institute University of Biomedical Sciences University of Córdoba (IUCBC), Cordoba, Argentina, ⁸Department of Autoimmune Diseases, ICMiD, Hospital Clínic Barcelona, Spain., Barcelona, Spain, ⁹Unidad de Investigación Biomédica 02, Unidad de Investigación en Epidemiología Clínica, Centro Médico Nacional de Occidente (CMNO), Instituto Mexicano del Seguro Social (IMSS), Hospital de Especialidades, Guadalajara, Guadalajara, Mexico, ¹⁰Programa de Doctorado en Ciencias Médicas, Centro Universitario de Investigaciones Biomédicas (CUIB), Universidad de Colima, Colima, Mexico, Mexico, Mexico, ¹¹Agency for Health Quality and Assessment of Catalonia (AQuAS). Ministry of Health, Catalonia, Barcelona, Spain, ¹²Department of Autoimmune Diseases, ICMiD, Hospital Clínic Barcelona., Barcelona, Spain
Background/Purpose: To analyse the prevalence of autoimmune diseases (ADs) in Catalonia by using a public big data program (Public Data Analysis for Health Research and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].